<DOC>
	<DOCNO>NCT01686932</DOCNO>
	<brief_summary>Vildagliptin Sitagliptin belong class DPP-4 inhibitor , differ pharmacokinetic profile well approve application ( Vildagliptin , 2x 50 mg daily , Sitagliptin , 1x 100 mg daily ) . This lead distinct result regard postprandial blood-glucose normalization well protective property regard hypoglycemic episode - especially night . Additionally , type 1 diabetic patient correlation describe hypoglycemia abnormal heart function ( QTc-elongation ) , severe consequence patient . This study aim evaluation potency drug prevent and/or reduce hypoglycemic event insulin-dependent type-2 diabetic furthermore evaluate correlation hypoglycemic episode change heart-function measure Holter-ECG . The hypothesis test , vildagliptin lead favourable glycemic profile sitagliptin potent protect nocturnal abnormality heart-function cause undetected hypoglycemic episode .</brief_summary>
	<brief_title>Vildagliptin v Sitagliptin add-on Insulin - Impact Glycemic Profile Correlation Hypoglycemic Episodes Heart Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Written informed consent must obtain assessment perform . 2 . Ability comply study requirement . 3 . Patients Type 2 diabetes treat stable , twice daily dos ( minimal dose 0.3 unit/kg/day ) basal longacting intermediateacting insulin alone premixed combination rapidacting shortacting insulin least 12 week prior Visit 1 . Stable defined ±10 % Visit 1 dose previous 12 week . 4 . Patients receive metformin must stable dose metformin ( least 1500 mg daily maximally tolerate dose ) least 12 week prior Visit 1 . 5 . HbA1c ≥7.5 ≤ 9,0 % Visit 1 6 . Known CV disease base documented history one predefined criterion 7 . Age : ≥40 ≤80 year Visit 1 1 . FPG ≥ 270 mg/dL ( 15 mmol/L ) Visit 1 . 2 . Use following medication assess Visit 1 : 1. rapid short act insulin except premixed formulation intermediate longacting insulin ; insulin administration frequently twicedaily , total insulin dose &lt; 0.3 unit/kg/day past 12 week 2. use oral antidiabetic medication GLP1 analogues within last 12 week , except metformin 3. use weight control product include weightloss medication last 12 week . 4. use oral ( ≥7 consecutive day ) chronic parenteral intraarticular corticosteroid treatment within last 8 week . Inhaled topical steroid without systemic effect allow . 5. treatment growth hormone within previous 6 month . 6. treatment drug know frequent toxicity major organ , may interfere interpretation efficacy safety data study . 3. history evidence follow Visit 1 : 1. acute metabolic condition ketoacidosis , lactic acidosis hyperosmolar state ( include precoma coma ) within past 6 month . 2. current diagnosis congestive heart failure ( NYHA III IV ) . 3. myocardial infarction within past 6 month . 4. coronary artery bypass surgery percutaneous coronary intervention within past 6 month . 5 . Stroke , transient ischemic attack , reversible ischemic neurologic deficit within past 6 month . 6. unstable angina within past 6 month . 7. sustain clinically relevant ventricular arrhythmia ( patient premature ventricular contraction deem clinically significant may enrol ) . 8 . Patients permanent atrial fibrillation pacemaker . 9. active substance abuse , alcohol abuse history alcoholrelated disease within past 2 year . 10. type 1 diabetes , monogenic diabetes , diabetes result pancreatic injury , secondary form diabetes ( e.g . Cushing 's syndrome acromegalyassociated diabetes ) . 11. malignancy organ system ( localize basal cell carcinoma skin ) treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 12. hepatic disorder define : acute chronic liver disease , evidence hepatitis , cirrhosis portal hypertension . history image abnormality suggest liver disease ( except hepatic steatosis ) , portal hypertension , capsule scalloping , cirrhosis . 13. acute infection may affect blood glucose control within past 4 week . 4. follow significant laboratory abnormality assess Visit 1 : 1. clinically significant increase reduction thyroid stimulate hormone ( TSH ) outside normal range . 2. clinically significant renal dysfunction : glomerular filtration rate ( GFR ) &lt; 50 mL/min/1.73m2 ( via MDRD formula ) . 3 . Patients metformin GFR &lt; 60 mL/min/1.73m2 ( via MDRD formula ) . 4. alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2 x upper limit normal ( ULN ) Visit 1 , confirm repeat measurement within 3 working day . 5. total bilirubin &gt; 2 x ULN and/or direct bilirubin &gt; 1 x ULN confirm repeated measurement within 3 working day . 6. positive Hepatitis B surface antigen ( HBsAg ) . 7. positive Hepatitis C virus ( HCV ) antibody test ( antiHCV ) . 8. elevate fast triglyceride ( TGs ) &gt; 500mg/dL ( 5.65mmol/L ) , confirm repeat measurement within 3 working day . 9. clinically significant laboratory abnormality , opinion investigator , cause patient consider inappropriate inclusion study . 5. follow electrocardiographic abnormality Visit 1 : 1. second third degree atrioventricular block . 2 . A QTc &gt; 440 ms. 3. clinically significant electrocardiogram ( ECG ) abnormality , opinion investigator , may cause patient consider inappropriate inclusion study Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>vildagliptin</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>continuous glucose monitoring ( CGM )</keyword>
	<keyword>glycemic fluctuation</keyword>
	<keyword>MAGE</keyword>
	<keyword>impact hypoglycemia heart function ( cardiac dysfuction measure via ECG )</keyword>
	<keyword>difference glycemic profile vildagliptin compare sitagliptin</keyword>
</DOC>